Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein
Coronavirus disease 2019 caused by the novel human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a major threat to public health worldwide. To deal with the needs of vaccine, we developed four DNA vaccine candidates against SARS-CoV-2, based on the full-length spike (S) o...
Gespeichert in:
| Veröffentlicht in: | Virology (New York, N.Y.) N.Y.), 2022-08, Vol.573, p.118-123 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 123 |
|---|---|
| container_issue | |
| container_start_page | 118 |
| container_title | Virology (New York, N.Y.) |
| container_volume | 573 |
| creator | Lim, Heeji Kim, Se Eun Lee, Yun Ha Hwang, Yun-Ho Kim, Su Hwan Kim, Mi Young Chung, Gyung Tae Kim, You-Jin Kim, Dokeun Lee, Jung-Ah |
| description | Coronavirus disease 2019 caused by the novel human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a major threat to public health worldwide. To deal with the needs of vaccine, we developed four DNA vaccine candidates against SARS-CoV-2, based on the full-length spike (S) or truncated S protein. Following mice vaccination, we measured T-cell response and antigen-specific neutralizing antibody (NAb) titer. All four candidates induced humoral immune responses, including elevated levels of total IgG and NAbs, and cell-mediated immune responses, including multiple cytokine expression. However, the full-length S DNA vaccine enhanced the immune responses most significantly. We then evaluated its appropriate antigen dose and vaccination schedule. Although all immunized groups showed higher immune response than the control group, inoculation with 50 μg antigen led to the highest NAb titer. Immunity was significantly increased after the third inoculation. Thus, the full-length S DNA vaccine can potentially prevent SARS-CoV-2 infection.
•We developed four DNA vaccine candidates against SARS-CoV-2 based on spike protein.•They induced humoral and cell-mediated immune responses against SARS-CoV-2.•Inoculation with 50 μg antigen led to the highest neutralizing antibody titer.•Full-length spike DNA vaccine can potentially prevent SARS-CoV-2 infection. |
| doi_str_mv | 10.1016/j.virol.2022.06.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9185170</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0042682222000988</els_id><sourcerecordid>2681049477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-f8293ee684c7b74c1200dc87a4e76e0c5858eb72cc100b810c1b46a33e023d393</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi1ERZfCEyAhH7kkjB3Hdg4grZYClaoiUeBqOc5s6yWxFzu7Ut--LluqcoGTZfmb3zPzEfKKQc2Aybebeu9THGsOnNcgawD5hCwYdLKCRrCnZAEgeCU158fkec4bKHel4Bk5blrVsk6JBbk4m6ZdiFcYvPPzDY1r6mwY_GBnpJfLr5fVKv6oOP1wsaR765wPmGlvMw40BjpfI81b_xPpNsUZfXhBjtZ2zPjy_jwh3z-eflt9rs6_fDpbLc8rJzo-V2vNuwZRauFUr4RjHGBwWlmBSiK4Vrcae8WdYwC9ZuBYL6RtGgTeDE3XnJD3h9ztrp9wcBjmZEezTX6y6cZE683fL8Ffm6u4Nx3TLVNQAt7cB6T4a4d5NpPPDsfRBoy7bLhimrdSCPV_VJYGRVdWW9DmgLoUc064fuiIgbmTZjbmtzRzJ82ANEVaqXr9eJiHmj-WCvDuAGBZ6d5jMtl5DA4Hn9DNZoj-nx_cAqp7qIg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2681049477</pqid></control><display><type>article</type><title>Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lim, Heeji ; Kim, Se Eun ; Lee, Yun Ha ; Hwang, Yun-Ho ; Kim, Su Hwan ; Kim, Mi Young ; Chung, Gyung Tae ; Kim, You-Jin ; Kim, Dokeun ; Lee, Jung-Ah</creator><creatorcontrib>Lim, Heeji ; Kim, Se Eun ; Lee, Yun Ha ; Hwang, Yun-Ho ; Kim, Su Hwan ; Kim, Mi Young ; Chung, Gyung Tae ; Kim, You-Jin ; Kim, Dokeun ; Lee, Jung-Ah</creatorcontrib><description>Coronavirus disease 2019 caused by the novel human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a major threat to public health worldwide. To deal with the needs of vaccine, we developed four DNA vaccine candidates against SARS-CoV-2, based on the full-length spike (S) or truncated S protein. Following mice vaccination, we measured T-cell response and antigen-specific neutralizing antibody (NAb) titer. All four candidates induced humoral immune responses, including elevated levels of total IgG and NAbs, and cell-mediated immune responses, including multiple cytokine expression. However, the full-length S DNA vaccine enhanced the immune responses most significantly. We then evaluated its appropriate antigen dose and vaccination schedule. Although all immunized groups showed higher immune response than the control group, inoculation with 50 μg antigen led to the highest NAb titer. Immunity was significantly increased after the third inoculation. Thus, the full-length S DNA vaccine can potentially prevent SARS-CoV-2 infection.
•We developed four DNA vaccine candidates against SARS-CoV-2 based on spike protein.•They induced humoral and cell-mediated immune responses against SARS-CoV-2.•Inoculation with 50 μg antigen led to the highest neutralizing antibody titer.•Full-length spike DNA vaccine can potentially prevent SARS-CoV-2 infection.</description><identifier>ISSN: 0042-6822</identifier><identifier>EISSN: 1096-0341</identifier><identifier>DOI: 10.1016/j.virol.2022.06.006</identifier><identifier>PMID: 35751974</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; antigens ; Brief Communication ; COVID-19 - prevention & control ; COVID-19 infection ; COVID-19 Vaccines - genetics ; cytokines ; DNA ; DNA vaccine ; Humans ; immune response ; immunogenicity ; Mice ; public health ; recombinant vaccines ; SARS-CoV-2 ; SARS-CoV-2 - genetics ; Severe acute respiratory syndrome coronavirus 2 ; Spike Glycoprotein, Coronavirus - genetics ; Spike protein ; T-lymphocytes ; Vaccination ; Vaccines, DNA ; Viral Vaccines ; virology</subject><ispartof>Virology (New York, N.Y.), 2022-08, Vol.573, p.118-123</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Inc.</rights><rights>2022 The Authors 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-f8293ee684c7b74c1200dc87a4e76e0c5858eb72cc100b810c1b46a33e023d393</citedby><cites>FETCH-LOGICAL-c492t-f8293ee684c7b74c1200dc87a4e76e0c5858eb72cc100b810c1b46a33e023d393</cites><orcidid>0000-0002-9292-3499</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0042682222000988$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35751974$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lim, Heeji</creatorcontrib><creatorcontrib>Kim, Se Eun</creatorcontrib><creatorcontrib>Lee, Yun Ha</creatorcontrib><creatorcontrib>Hwang, Yun-Ho</creatorcontrib><creatorcontrib>Kim, Su Hwan</creatorcontrib><creatorcontrib>Kim, Mi Young</creatorcontrib><creatorcontrib>Chung, Gyung Tae</creatorcontrib><creatorcontrib>Kim, You-Jin</creatorcontrib><creatorcontrib>Kim, Dokeun</creatorcontrib><creatorcontrib>Lee, Jung-Ah</creatorcontrib><title>Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein</title><title>Virology (New York, N.Y.)</title><addtitle>Virology</addtitle><description>Coronavirus disease 2019 caused by the novel human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a major threat to public health worldwide. To deal with the needs of vaccine, we developed four DNA vaccine candidates against SARS-CoV-2, based on the full-length spike (S) or truncated S protein. Following mice vaccination, we measured T-cell response and antigen-specific neutralizing antibody (NAb) titer. All four candidates induced humoral immune responses, including elevated levels of total IgG and NAbs, and cell-mediated immune responses, including multiple cytokine expression. However, the full-length S DNA vaccine enhanced the immune responses most significantly. We then evaluated its appropriate antigen dose and vaccination schedule. Although all immunized groups showed higher immune response than the control group, inoculation with 50 μg antigen led to the highest NAb titer. Immunity was significantly increased after the third inoculation. Thus, the full-length S DNA vaccine can potentially prevent SARS-CoV-2 infection.
•We developed four DNA vaccine candidates against SARS-CoV-2 based on spike protein.•They induced humoral and cell-mediated immune responses against SARS-CoV-2.•Inoculation with 50 μg antigen led to the highest neutralizing antibody titer.•Full-length spike DNA vaccine can potentially prevent SARS-CoV-2 infection.</description><subject>Animals</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>antigens</subject><subject>Brief Communication</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 infection</subject><subject>COVID-19 Vaccines - genetics</subject><subject>cytokines</subject><subject>DNA</subject><subject>DNA vaccine</subject><subject>Humans</subject><subject>immune response</subject><subject>immunogenicity</subject><subject>Mice</subject><subject>public health</subject><subject>recombinant vaccines</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 - genetics</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike Glycoprotein, Coronavirus - genetics</subject><subject>Spike protein</subject><subject>T-lymphocytes</subject><subject>Vaccination</subject><subject>Vaccines, DNA</subject><subject>Viral Vaccines</subject><subject>virology</subject><issn>0042-6822</issn><issn>1096-0341</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhi1ERZfCEyAhH7kkjB3Hdg4grZYClaoiUeBqOc5s6yWxFzu7Ut--LluqcoGTZfmb3zPzEfKKQc2Aybebeu9THGsOnNcgawD5hCwYdLKCRrCnZAEgeCU158fkec4bKHel4Bk5blrVsk6JBbk4m6ZdiFcYvPPzDY1r6mwY_GBnpJfLr5fVKv6oOP1wsaR765wPmGlvMw40BjpfI81b_xPpNsUZfXhBjtZ2zPjy_jwh3z-eflt9rs6_fDpbLc8rJzo-V2vNuwZRauFUr4RjHGBwWlmBSiK4Vrcae8WdYwC9ZuBYL6RtGgTeDE3XnJD3h9ztrp9wcBjmZEezTX6y6cZE683fL8Ffm6u4Nx3TLVNQAt7cB6T4a4d5NpPPDsfRBoy7bLhimrdSCPV_VJYGRVdWW9DmgLoUc064fuiIgbmTZjbmtzRzJ82ANEVaqXr9eJiHmj-WCvDuAGBZ6d5jMtl5DA4Hn9DNZoj-nx_cAqp7qIg</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Lim, Heeji</creator><creator>Kim, Se Eun</creator><creator>Lee, Yun Ha</creator><creator>Hwang, Yun-Ho</creator><creator>Kim, Su Hwan</creator><creator>Kim, Mi Young</creator><creator>Chung, Gyung Tae</creator><creator>Kim, You-Jin</creator><creator>Kim, Dokeun</creator><creator>Lee, Jung-Ah</creator><general>Elsevier Inc</general><general>The Authors. Published by Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9292-3499</orcidid></search><sort><creationdate>20220801</creationdate><title>Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein</title><author>Lim, Heeji ; Kim, Se Eun ; Lee, Yun Ha ; Hwang, Yun-Ho ; Kim, Su Hwan ; Kim, Mi Young ; Chung, Gyung Tae ; Kim, You-Jin ; Kim, Dokeun ; Lee, Jung-Ah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-f8293ee684c7b74c1200dc87a4e76e0c5858eb72cc100b810c1b46a33e023d393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>antigens</topic><topic>Brief Communication</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 infection</topic><topic>COVID-19 Vaccines - genetics</topic><topic>cytokines</topic><topic>DNA</topic><topic>DNA vaccine</topic><topic>Humans</topic><topic>immune response</topic><topic>immunogenicity</topic><topic>Mice</topic><topic>public health</topic><topic>recombinant vaccines</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 - genetics</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike Glycoprotein, Coronavirus - genetics</topic><topic>Spike protein</topic><topic>T-lymphocytes</topic><topic>Vaccination</topic><topic>Vaccines, DNA</topic><topic>Viral Vaccines</topic><topic>virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lim, Heeji</creatorcontrib><creatorcontrib>Kim, Se Eun</creatorcontrib><creatorcontrib>Lee, Yun Ha</creatorcontrib><creatorcontrib>Hwang, Yun-Ho</creatorcontrib><creatorcontrib>Kim, Su Hwan</creatorcontrib><creatorcontrib>Kim, Mi Young</creatorcontrib><creatorcontrib>Chung, Gyung Tae</creatorcontrib><creatorcontrib>Kim, You-Jin</creatorcontrib><creatorcontrib>Kim, Dokeun</creatorcontrib><creatorcontrib>Lee, Jung-Ah</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Virology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lim, Heeji</au><au>Kim, Se Eun</au><au>Lee, Yun Ha</au><au>Hwang, Yun-Ho</au><au>Kim, Su Hwan</au><au>Kim, Mi Young</au><au>Chung, Gyung Tae</au><au>Kim, You-Jin</au><au>Kim, Dokeun</au><au>Lee, Jung-Ah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein</atitle><jtitle>Virology (New York, N.Y.)</jtitle><addtitle>Virology</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>573</volume><spage>118</spage><epage>123</epage><pages>118-123</pages><issn>0042-6822</issn><eissn>1096-0341</eissn><abstract>Coronavirus disease 2019 caused by the novel human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a major threat to public health worldwide. To deal with the needs of vaccine, we developed four DNA vaccine candidates against SARS-CoV-2, based on the full-length spike (S) or truncated S protein. Following mice vaccination, we measured T-cell response and antigen-specific neutralizing antibody (NAb) titer. All four candidates induced humoral immune responses, including elevated levels of total IgG and NAbs, and cell-mediated immune responses, including multiple cytokine expression. However, the full-length S DNA vaccine enhanced the immune responses most significantly. We then evaluated its appropriate antigen dose and vaccination schedule. Although all immunized groups showed higher immune response than the control group, inoculation with 50 μg antigen led to the highest NAb titer. Immunity was significantly increased after the third inoculation. Thus, the full-length S DNA vaccine can potentially prevent SARS-CoV-2 infection.
•We developed four DNA vaccine candidates against SARS-CoV-2 based on spike protein.•They induced humoral and cell-mediated immune responses against SARS-CoV-2.•Inoculation with 50 μg antigen led to the highest neutralizing antibody titer.•Full-length spike DNA vaccine can potentially prevent SARS-CoV-2 infection.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35751974</pmid><doi>10.1016/j.virol.2022.06.006</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-9292-3499</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0042-6822 |
| ispartof | Virology (New York, N.Y.), 2022-08, Vol.573, p.118-123 |
| issn | 0042-6822 1096-0341 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9185170 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Animals Antibodies, Neutralizing Antibodies, Viral antigens Brief Communication COVID-19 - prevention & control COVID-19 infection COVID-19 Vaccines - genetics cytokines DNA DNA vaccine Humans immune response immunogenicity Mice public health recombinant vaccines SARS-CoV-2 SARS-CoV-2 - genetics Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - genetics Spike protein T-lymphocytes Vaccination Vaccines, DNA Viral Vaccines virology |
| title | Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T23%3A16%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20candidate%20SARS-CoV-2%20DNA%20vaccines%20based%20on%20the%20spike%20protein&rft.jtitle=Virology%20(New%20York,%20N.Y.)&rft.au=Lim,%20Heeji&rft.date=2022-08-01&rft.volume=573&rft.spage=118&rft.epage=123&rft.pages=118-123&rft.issn=0042-6822&rft.eissn=1096-0341&rft_id=info:doi/10.1016/j.virol.2022.06.006&rft_dat=%3Cproquest_pubme%3E2681049477%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2681049477&rft_id=info:pmid/35751974&rft_els_id=S0042682222000988&rfr_iscdi=true |